Novozymes Biopharma has entered a collaboration with Janssen Research & Development, LLC under which Janssen will evaluate Novozymes’s engineered albumin-based VELTIS technology for potential drug candidates. Novozymes’ VELTIS technology represents a series of engineered human albumins that in combination with a drug candidate, offers the potential for control of the therapeutic half-life, which allows for reducing the dosing frequency of drugs from daily to every two weeks or monthly....